Product image of Iodure [123i] De Sodium Cis Bio International (Sodium Iodide (123 I)) supplied by GNH India

Iodure [123i] De Sodium Cis Bio International

Active Ingredient:
Sodium Iodide (123 I)
Origin:
EU

Iodure [123i] De Sodium Cis Bio International (Sodium Iodide (123 I))

Sodium Iodide, the active ingredient in Iodure [123i] De Sodium Cis Bio International, is a diagnostic radiopharmaceutical presented as a sterile aqueous solution for intravenous use. It is employed to visualize thyroid tissue and assess its functional status in patients undergoing nuclear medicine examinations.

GNH India supplies Iodure [123i] De Sodium Cis Bio International as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Manufacturer / TM Owner

Cis Bio International

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Iodure [123i] De Sodium Cis Bio International is a radiopharmaceutical used in thyroid‑related diagnostic pathways.

  • Thyroid imaging: provides functional and anatomical assessment of thyroid tissue for routine scans.
  • Thyroid nodule evaluation: helps differentiate benign from malignant nodules by measuring iodine uptake.
  • Thyroid cancer staging: assists in detecting residual or metastatic disease after treatment.

How It Works

  • Sodium Iodide (I‑123) is a radioactive isotope that mimics natural iodine. After intravenous injection, it is actively transported into thyroid follicular cells via the sodium‑iodide symporter. The emitted gamma photons are captured by a gamma camera, producing high‑resolution images that reflect the distribution and activity of thyroid tissue, enabling functional assessment and anatomical localization.

Side Effects

Adverse reactions may occur following administration of Iodure [123i] De Sodium Cis Bio International.

Common Side Effects

  • Nausea or vomiting: mild gastrointestinal upset after injection.
  • Injection site pain or erythema: transient discomfort at the venipuncture site.
  • Headache: brief, self‑limiting headache reported by some patients.

Serious or Rare Side Effects

  • Allergic reaction: urticaria, bronchospasm, or anaphylaxis requiring immediate medical attention.
  • Radiation thyroiditis: inflammation of the thyroid gland due to radiation exposure.
  • Severe hypotension: rare drop in blood pressure following rapid intravenous administration.

Precautions & Warnings

Prior to using Iodure [123i] De Sodium Cis Bio International, consider the following safety measures.

  • Pregnancy: risk unknown; avoid unless clearly needed.
  • Breastfeeding: risk unknown; consider discontinuation during treatment.
  • Thyroid function: assess baseline thyroid status before administration.
  • Renal impairment: monitor renal function as clearance may be affected.
  • Iodine allergy: screen patients for known hypersensitivity to iodine compounds.
  • Store at ambient temperature: keep in original shielded container, protect from light and moisture.

Avoid Interactions

Iodure [123i] De Sodium Cis Bio International may interact with other agents.

Major Interactions (Avoid)

  • Thyroid hormone therapy: can reduce radiotracer uptake and compromise imaging quality.
  • Antithyroid drugs (e.g., methimazole, propylthiouracil): diminish iodine uptake, leading to false‑negative results.
  • Iodine‑containing contrast agents: block thyroid uptake if administered within 2–4 weeks.

Moderate Interactions (Monitor Closely)

  • Lithium therapy: may alter thyroid iodine handling and affect image interpretation.
  • Amiodarone: high iodine load can interfere with tracer distribution.
  • Diuretics: may affect renal clearance of the radiopharmaceutical, requiring monitoring.

Frequently Asked Questions

Iodure [123i] De Sodium Cis Bio International is a diagnostic radiopharmaceutical containing Sodium Iodide (I‑123). It is used primarily for thyroid imaging, helping clinicians evaluate thyroid function, assess nodules, and stage thyroid cancer by providing clear gamma‑camera images of iodine uptake.

Sodium Iodide (I‑123) mimics natural iodine and is taken up by thyroid follicular cells via the sodium‑iodide symporter. The radioactive isotope emits gamma photons that are detected by a gamma camera, producing detailed images that reflect the functional activity and distribution of thyroid tissue.

The administered activity of Iodure [123i] De Sodium Cis Bio International is determined by the prescribing physician based on the specific diagnostic protocol, patient weight, and clinical indication. Dosage is individualized and should follow local nuclear medicine guidelines.

The safety of Iodure [123i] in pregnancy and breastfeeding has not been established. It should be avoided unless the diagnostic benefit clearly outweighs potential risks, and the decision should be made in consultation with a qualified healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Iodure [123i] uses I‑123, which offers a favorable half‑life and gamma emission energy for high‑resolution imaging with lower radiation dose compared with I‑131. Unlike technetium‑99m pertechnetate, I‑123 is actively organified in the thyroid, providing more accurate functional information.

Store the product at ambient temperature, preferably below 25 °C, in its original shielded container. Protect it from light, moisture, and physical damage. Ensure that the vial remains sealed until use and follow local radiation safety regulations during handling.

Iodure [123i] is administered intravenously by a qualified nuclear medicine professional. The sterile solution is injected into a peripheral vein, after which the patient may wait a short period before imaging to allow optimal thyroid uptake of the tracer.

Serious risks include allergic reactions ranging from urticaria to anaphylaxis, radiation‑induced thyroiditis, and rare severe hypotension following rapid injection. Immediate medical attention is required if any signs of a severe reaction develop during or after administration.

Patients with a known hypersensitivity to iodine or iodide compounds, those who have received recent iodine‑containing contrast agents, and individuals for whom the diagnostic benefit does not outweigh potential radiation exposure should not receive this radiopharmaceutical.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Sodium Iodide (123 I)

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT